{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:31:11Z","timestamp":1792992671414,"version":"4.5.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The management of blood pressure (BP) in secondary prevention after acute myocardial infarction (AMI) remains a matter of debate. Since no dedicated trials have specifically addressed BP control in patients recovering from an acute coronary syndrome, there are no evidence-based, prospective data to define precise BP targets in this population. Moreover, major international guidelines devote surprisingly little attention to BP management in the post-AMI setting, despite its recognized importance in reducing recurrent cardiovascular events. On one hand, BP-lowering may improve cardiac function by reducing afterload and myocardial oxygen consumption and by facilitating favourable ventricular remodelling. On the other hand, the concept of a J-shaped association\u2014whereby excessive lowering of diastolic blood pressure may paradoxically increase cardiovascular risk, particularly in the early post-AMI period\u2014remains a matter of ongoing uncertainty. Despite decades of investigation, this issue has not been definitively resolved and continues to raise debate within both the scientific community and among clinicians. In this review, we examine the current evidence supporting BP control in the context of secondary prevention following AMI, with an updated focus on the ongoing debate surrounding the potential implications of the J-shaped phenomenon.<\/jats:p>","DOI":"10.1093\/cvr\/cvaf145","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:19:37Z","timestamp":1756120777000},"page":"1989-1996","source":"Crossref","is-referenced-by-count":4,"title":["Blood pressure management in secondary prevention after myocardial infarction"],"prefix":"10.1093","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome , Via di Grottarossa 1035-1035, 00189 Rome ,","place":["Italy"]},{"name":"IRCCS S. Raffaele , Via della Pisana 235, 00163 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Giovanna","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome , Via di Grottarossa 1035-1035, 00189 Rome ,","place":["Italy"]},{"name":"Cardiology Unit, Sant'Andrea University Hospital , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz J","family":"Guzik","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Sciences, BHF Cardiovascular Research Centre, University of Edinburgh , Edinburgh ,","place":["UK"]},{"name":"Department of Medicine, Jagiellonian University , Krakow ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8094-1841","authenticated-orcid":false,"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[{"name":"UCL Hospitals Biomedical Research Centre, University College London (UCL), Institute of Cardiovascular Science, National Institute for Health Research , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz H","family":"Messerli","sequence":"additional","affiliation":[{"name":"Kantonsspital Luzern and Department of BioMedical Research, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2025102811282275300_cvaf145-B1","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCRESAHA.119.314724","article-title":"Implications of guidelines for hypertension management in Europe","volume":"124","author":"Volpe","year":"2019","journal-title":"Circ Res"},{"key":"2025102811282275300_cvaf145-B3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025102811282275300_cvaf145-B4","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B5","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2025102811282275300_cvaf145-B6","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1503\/cmaj.241770","article-title":"Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care","volume":"197","author":"Goupil","year":"2025","journal-title":"CMAJ"},{"key":"2025102811282275300_cvaf145-B7","doi-asserted-by":"crossref","first-page":"107230","DOI":"10.1016\/j.vph.2023.107230","article-title":"Hypertension, coronary artery disease and myocardial ischemic syndromes","volume":"153","author":"Volpe","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"2025102811282275300_cvaf145-B8","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/eurheartj\/ehaa054","article-title":"The muddy waters of the J-curve and coronary revascularization","volume":"41","author":"Messerli","year":"2020","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B9","first-page":"100065","article-title":"The diastolic blood pressure J-curve revisited: an update","volume":"12","author":"Filippone","year":"2021","journal-title":"Am Heart J Plus"},{"key":"2025102811282275300_cvaf145-B10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(78)92288-2","article-title":"Re-examination of some of the framingham blood-pressure data","volume":"312","author":"Anderson","year":"1978","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(87)90231-5","article-title":"Benefits and potential harm of lowering high blood pressure","volume":"1","author":"Cruickshank","year":"1987","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.1991.03460040065031","article-title":"The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?","volume":"265","author":"Farnett","year":"1991","journal-title":"JAMA"},{"key":"2025102811282275300_cvaf145-B13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/HYPERTENSIONAHA.114.04581","article-title":"Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events? The Framingham Heart Study","volume":"65","author":"Franklin","year":"2015","journal-title":"Hypertension"},{"key":"2025102811282275300_cvaf145-B15","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"2025102811282275300_cvaf145-B16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025102811282275300_cvaf145-B17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"N Engl J Med"},{"key":"2025102811282275300_cvaf145-B18","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B19","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","article-title":"Treating to new targets steering committee and investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the treating to new targets (TNT) trial","volume":"31","author":"Bangalore","year":"2010","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.117.030342","article-title":"Curve in patients randomly assigned to different systolic blood pressure targets. An experimental approach to an observational paradigm","volume":"136","author":"Kalkman","year":"2017","journal-title":"Circulation"},{"key":"2025102811282275300_cvaf145-B21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102811282275300_cvaf145-B22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators","year":"2008","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B23","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"B\u00f6hm","year":"2017","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B24","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1093\/eurheartj\/ehy287","article-title":"Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120\u2013140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"39","author":"B\u00f6hm","year":"2018","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","article-title":"Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control","volume":"68","author":"McEvoy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025102811282275300_cvaf145-B26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.amjcard.2017.07.094","article-title":"Relation of diastolic blood pressure and coronary artery calcium to coronary events and outcomes (from the multi-ethnic study of atherosclerosis)","volume":"120","author":"Rahman","year":"2017","journal-title":"Am J Cardiol"},{"key":"2025102811282275300_cvaf145-B27","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/eurheartj\/ehx809","article-title":"SAVOR-TIMI 53 investigators. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk","volume":"39","author":"Bergmark","year":"2018","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jash.2018.04.004","article-title":"Diastolic blood pressure and risk profile in renal and cardiovascular diseases. Results from the SPRINT trial","volume":"12","author":"Del Pinto","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"2025102811282275300_cvaf145-B29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.117.10177","article-title":"Effect of lowering diastolic pressure in patients with and without cardiovascular disease: analysis of the SPRINT (systolic blood pressure intervention trial)","volume":"71","author":"Khan","year":"2018","journal-title":"Hypertension"},{"key":"2025102811282275300_cvaf145-B30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.amjmed.2018.05.022","article-title":"Diastolic hypotension may attenuate benefits from intensive systolic targets: secondary analysis of a randomized controlled trial","volume":"131","author":"Lee","year":"2018","journal-title":"Am J Med"},{"key":"2025102811282275300_cvaf145-B31","doi-asserted-by":"crossref","first-page":"e2037554","DOI":"10.1001\/jamanetworkopen.2020.37554","article-title":"Evaluation of optimal diastolic blood pressure range among adults with treated systolic blood pressure less than 130 mm hg","volume":"4","author":"Li","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025102811282275300_cvaf145-B32","author":"OpenAI","year":"2023"},{"key":"2025102811282275300_cvaf145-B33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.CIR.76.6.1183","article-title":"Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care","volume":"76","author":"Klocke","year":"1987","journal-title":"Circulation"},{"key":"2025102811282275300_cvaf145-B34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000175818","article-title":"Clinical importance of coronary perfusion pressure in the hypertensive patient with left ventricular hypertrophy","volume":"81","author":"Cruickshank","year":"1992","journal-title":"Cardiology"},{"key":"2025102811282275300_cvaf145-B35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/01.CIR.83.3.845","article-title":"Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle","volume":"83","author":"Polese","year":"1991","journal-title":"Circulation"},{"key":"2025102811282275300_cvaf145-B36","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.105.603050","article-title":"Evidence of a dominant backward-propagating \u201csuction\u201d wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy","volume":"113","author":"Davies","year":"2006","journal-title":"Circulation"},{"key":"2025102811282275300_cvaf145-B37","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","article-title":"The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?","volume":"54","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025102811282275300_cvaf145-B38","doi-asserted-by":"crossref","first-page":"13294","DOI":"10.3390\/ijms252413294","article-title":"Systemic and cardiac microvascular dysfunction in hypertension","volume":"25","author":"Durante","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025102811282275300_cvaf145-B39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(02)02708-X","article-title":"Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension","volume":"90","author":"Galderisi","year":"2002","journal-title":"Am J Cardiol"},{"key":"2025102811282275300_cvaf145-B40","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1097\/HJH.0000000000000338","article-title":"The blunting of coronary flow reserve in hypertension with left ventricular hypertrophy is transmural and correlates with systolic blood pressure","volume":"32","author":"Rimoldi","year":"2014","journal-title":"J Hypertens"},{"key":"2025102811282275300_cvaf145-B41","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehab775","article-title":"Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis","volume":"43","author":"Kelshiker","year":"2022","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5603\/CJ.a2017.0109","article-title":"Low diastolic blood pressure is associated with a high atherosclerotic burden in patients with obstructive coronary artery disease","volume":"25","author":"Senthong","year":"2018","journal-title":"Cardiol J"},{"key":"2025102811282275300_cvaf145-B43","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.jacc.2019.03.493","article-title":"Melbourne interventional group investigators","volume":"73","author":"Warren","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025102811282275300_cvaf145-B44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-126-10-199705150-00002","article-title":"Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators","volume":"126","author":"Gueyffier","year":"1997","journal-title":"Ann Intern Med"},{"key":"2025102811282275300_cvaf145-B45","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.117.030342","article-title":"Curve in patients randomly assigned to different systolic blood pressure targets: an experimental approach to an observational paradigm","volume":"136","author":"Kalkman","year":"2017","journal-title":"Circulation"},{"key":"2025102811282275300_cvaf145-B46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/hr.2012.165","article-title":"Hypertension and the J-curve phenomenon: implications for tight blood pressure control","volume":"36","author":"Angeli","year":"2013","journal-title":"Hypertens Res"},{"key":"2025102811282275300_cvaf145-B47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/HYPERTENSIONAHA.113.01018","article-title":"Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement","volume":"63","author":"Verdecchia","year":"2014","journal-title":"Hypertension"},{"key":"2025102811282275300_cvaf145-B48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/eurheartj\/ehae803","article-title":"Type 2 myocardial infarction: challenges in diagnosis and treatment","volume":"46","author":"Chapman","year":"2025","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/CIRCULATIONAHA.119.043100","article-title":"Incidence, trends, and outcomes of type 2 myocardial infarction in a community cohort","volume":"141","author":"Raphael","year":"2020","journal-title":"Circulation"},{"key":"2025102811282275300_cvaf145-B50","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2021.09.013","article-title":"Optimal BP targets to prevent stroke and MI: is there a lesser of 2 evils?","volume":"78","author":"Messerli","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025102811282275300_cvaf145-B51","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.jacc.2021.08.035","article-title":"Contributions of systolic and diastolic blood pressures to cardiovascular outcomes in the ALLHAT study","volume":"78","author":"Itoga","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025102811282275300_cvaf145-B52","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/ajh.2011.105","article-title":"Redefining blood pressure targets in high-risk patients? Lessons from coronary endpoints in recent randomized clinical trials","volume":"24","author":"Volpe","year":"2011","journal-title":"Am J Hypertens"},{"key":"2025102811282275300_cvaf145-B53","doi-asserted-by":"crossref","first-page":"798958","DOI":"10.3389\/fmed.2021.798958","article-title":"Endothelial dysfunction in hypertension: current concepts and clinical implications","volume":"8","author":"Gallo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025102811282275300_cvaf145-B54","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.3390\/jcm12082883","article-title":"New insights into pathophysiology and new risk factors for ACS","volume":"12","author":"Nardin","year":"2023","journal-title":"J Clin Med"},{"key":"2025102811282275300_cvaf145-B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajh\/hpac093","article-title":"State of the art review: vascular remodeling in hypertension","volume":"36","author":"Rizzoni","year":"2023","journal-title":"Am J Hypertens"},{"key":"2025102811282275300_cvaf145-B56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/HJH.0000000000003890","article-title":"Impact of hypertension on mortality in patients with ST-elevation myocardial infarction undergoing primary angioplasty: insights from the international multicenter ISACS-STEMI registry","volume":"43","author":"De Luca","year":"2025","journal-title":"J Hypertens"},{"key":"2025102811282275300_cvaf145-B57","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41591-022-01974-1","article-title":"Effects of elevated systolic blood pressure on ischemic heart disease: a burden of proof study","volume":"28","author":"Razo","year":"2022","journal-title":"Nat Med"},{"key":"2025102811282275300_cvaf145-B58","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4070\/kcj.2017.0008","article-title":"Korean acute myocardial infarction registry investigators","volume":"47","author":"Park","year":"2017","journal-title":"Korean Circ J"},{"key":"2025102811282275300_cvaf145-B59","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"2025102811282275300_cvaf145-B60","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2025102811282275300_cvaf145-B61","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"2025102811282275300_cvaf145-B62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2011.250","article-title":"Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis","volume":"305","author":"Thompson","year":"2011","journal-title":"JAMA"},{"key":"2025102811282275300_cvaf145-B63","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B64","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B65","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"2025102811282275300_cvaf145-B66","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2025102811282275300_cvaf145-B67","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2017.12.026","article-title":"Is early and fast blood pressure control important in hypertension management?","volume":"254","author":"Volpe","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025102811282275300_cvaf145-B68","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B69","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B70","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"2025102811282275300_cvaf145-B71","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/STROKEAHA.116.013321","article-title":"Long-term risk of stroke in myocardial infarction survivors: thirty-year population-based cohort study","volume":"47","author":"Sundb\u00f8ll","year":"2016","journal-title":"Stroke"},{"key":"2025102811282275300_cvaf145-B72","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/eurheartj\/ehaf291","article-title":"Heart rate-lowering drugs and outcomes in hypertension and\/or cardiovascular disease: a meta-analysis","volume":"46","author":"Sanidas","year":"2025","journal-title":"Eur Heart J"},{"key":"2025102811282275300_cvaf145-B73","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/eurheartj\/ehaf310","article-title":"The double-edged sword of heart rate lowering in cardiovascular disease","volume":"46","author":"Messerli","year":"2025","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvaf145\/64140671\/cvaf145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/13\/1989\/64140671\/cvaf145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/13\/1989\/64140671\/cvaf145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:28:42Z","timestamp":1761665322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/121\/13\/1989\/8241941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":73,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvaf145","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,26]]}}}